New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

Event date: 
Tuesday, 26 November, 2019 to Thursday, 26 December, 2019

In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.